Ideaya Biosciences Inc (IDYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has a cash flow conversion efficiency ratio of -0.136x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-163.38 Million) by net assets ($1.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IDYA stock market capitalisation for the company's overall valuation and market capitalisation.
Ideaya Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Ideaya Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ideaya Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ideaya Biosciences Inc ranked by their cash flow conversion efficiency. Explore Ideaya Biosciences Inc (IDYA) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wesdome Gold Mines Ltd.
TO:WDO
|
0.168x |
|
Sinotruk Jinan Truck Co Ltd
SHE:000951
|
0.125x |
|
Auras Technology Co Ltd
TWO:3324
|
-0.044x |
|
CRISIL Limited
NSE:CRISIL
|
0.073x |
|
Monday.Com Ltd
NASDAQ:MNDY
|
0.138x |
|
Charoen Pokphand Foods Public Company Limited
F:NVAV
|
0.042x |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
0.058x |
|
Sai MicroElectronics Inc
SHE:300456
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ideaya Biosciences Inc from 2017 to 2025. View IDYA stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.02 Billion | $-71.10 Million | -0.070x | +70.27% |
| 2024-12-31 | $1.06 Billion | $-247.58 Million | -0.234x | -26.00% |
| 2023-12-31 | $621.09 Million | $-115.22 Million | -0.186x | +25.63% |
| 2022-12-31 | $349.45 Million | $-87.17 Million | -0.249x | -34.85% |
| 2021-12-31 | $301.51 Million | $-55.78 Million | -0.185x | -166.13% |
| 2020-12-31 | $198.27 Million | $55.46 Million | 0.280x | +171.44% |
| 2019-12-31 | $100.40 Million | $-39.31 Million | -0.392x | -169.39% |
| 2018-12-31 | $-48.95 Million | $-27.62 Million | 0.564x | -27.35% |
| 2017-12-31 | $-15.74 Million | $-12.22 Million | 0.777x | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more